30. Milling T.J. et al. Randomized, controlled clinical trial of point-of-care limited ultrasonography assistance of central venous cannulation: The Third Sonography Outcomes Assessment Program (SOAP-3) Trial* // Crit. Care Med. 2005. Vol. 33, № 8. P. 1764–1769.
31. Stathis A. et al. Long-term outcome following Helicobacter pylori eradication in a retrospective study of 105 patients with localized gastric marginal zone B-cell lymphoma of MALT type. // Ann. Oncol. Off. J. Eur. Soc. Med. Oncol. 2009. Vol. 20, № 6. P. 1086–1093.
32. Lossos I.S. et al. Rituximab for treatment of chemoimmunotherapy naive marginal zone lymphoma // Leuk. Lymphoma. Leuk Lymphoma, 2007. Vol. 48, № 8. P. 1630–1632.
33. Conconi A. et al. Clinical activity of rituximab in extranodal marginal zone B-cell lymphoma of MALT type // Blood. Blood, 2003. Vol. 102, № 8. P. 2741–2745.
34. Rolf D. et al. Development of Organ-Preserving Radiation Therapy in Gastric Marginal Zone Lymphoma // Cancers 2022, Vol. 14, Page 873. Multidisciplinary Digital Publishing Institute, 2022. Vol. 14, № 4. P. 873.
35. Fischbach W. MALT lymphoma: Forget surgery? // Dig. Dis. 2013. Vol. 31, № 1. P. 38–42.
36. Yahalom J. et al. Modern radiation therapy for extranodal lymphomas: Field and dose guidelines from the international lymphoma radiation oncology group // Int. J. Radiat. Oncol. Biol. Phys. Elsevier Inc., 2015. Vol. 92, № 1. P. 11–31.
37. Quéro L. et al. [Radiotherapy for localized gastric and orbital MALT lymphomas] // Cancer Radiother. Cancer Radiother, 2016. Vol. 20, № 6–7. P. 543–546.
38. Liang Y. et al. Long-term survival outcomes of patients with primary ocular adnexal MALT lymphoma: A large single-center cohort study // Cancer Med. Cancer Med, 2023. Vol. 12, № 3. P. 2514–2523.
39. Thieblemont C. et al. Treatment of splenic marginal zone B-cell lymphoma: an analysis of 81 patients // Clin. Lymphoma. Clin Lymphoma, 2002. Vol. 3, № 1. P. 41–47.
40. Ardeshna K.M. et al. Rituximab versus a watch-and-wait approach in patients with advanced-stage, asymptomatic, non-bulky follicular lymphoma: An open-label randomised phase 3 trial // Lancet Oncol. Lancet Publishing Group, 2014. Vol. 15, № 4. P. 424–435.
41. Kalpadakis C. et al. Rituximab monotherapy in splenic marginal zone lymphoma: prolonged responses and potential benefit from maintenance // Blood. Blood, 2018. Vol. 132, № 6. P. 666–670.
42. Hiddemann W. et al. Immunochemotherapy With Obinutuzumab or Rituximab for Previously Untreated Follicular Lymphoma in the GALLIUM Study: Influence of Chemotherapy on Efficacy and Safety. // J. Clin. Oncol. American Society of Clinical Oncology, 2018. Vol. 36, № 23. P. 2395–2404.
43. Wang Y. et al. Rituximab plus cladribine versus R-CHOP in frontline management of marginal zone lymphoma in China: a propensity-score matched multicenter study // Ann. Hematol. Ann Hematol, 2022. Vol. 101, № 10. P. 2139–2148.
44. Kang H.J. et al. Phase II trial of rituximab plus CVP combination chemotherapy for advanced stage marginal zone lymphoma as a first-line therapy: Consortium for Improving Survival of Lymphoma (CISL) study // Ann. Hematol. Ann Hematol, 2012. Vol. 91, № 4. P. 543–551.
45. Flinn I.W. et al. Randomized trial of bendamustine-rituximab or R-CHOP/R-CVP in first-line treatment of indolent NHL or MCL: the BRIGHT study // Blood. American Society of Hematology, 2014. Vol. 123, № 19. P. 2944–2952.
46. Laribi K. et al. The bendamustine plus rituximab regimen is active against primary nodal marginal zone B-cell lymphoma // Hematol. Oncol. Hematol Oncol, 2017. Vol. 35, № 4. P. 536–541.
47. Bonanni P. et al. Recommended vaccinations for asplenic and hyposplenic adult patients // Hum. Vaccin. Immunother. Hum Vaccin Immunother, 2017. Vol. 13, № 2. P. 359–368.
48. Dührsen U. et al. Rituximab maintenance therapy of follicular lymphoma in clinical practice // Cancer Med. Blackwell Publishing Ltd, 2018. Vol. 7, № 7. P. 2903–2912.
49. Bastos‐Oreiro M. et al. Maintenance therapy after R‐bendamistine vs R‐CHOP in first-line treatment of low-grade follicular lymphoma: a multicentre, retrospective GELTAMO study // Hematol. Oncol. Wiley, 2021. Vol. 39, № S2.
50. Sehn L.H. et al. Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label, multicentre, phase 3 trial // Lancet Oncol. Lancet Publishing Group, 2016. Vol. 17, № 8. P. 1081–1093.
51. Noy A. et al. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma // Blood. 2017. Vol. 129, № 16. P. 2224–2232.
52. Opat S. et al. The MAGNOLIA Trial: Zanubrutinib, a Next-Generation Bruton Tyrosine Kinase Inhibitor, Demonstrates Safety and Efficacy in Relapsed/Refractory Marginal Zone Lymphoma // Clin. Cancer Res. Clin Cancer Res, 2021. Vol. 27, № 23. P. 6323–6332.
53. Leonard J.P. et al. AUGMENT: A Phase III study of lenalidomide plus rituximab versus placebo plus rituximab in relapsed or refractory indolent lymphoma // Journal of Clinical Oncology. American Society of Clinical Oncology, 2019. Vol. 37, № 14. P. 1188–1199.
54. Procházka V. et al. Frontline intensive chemotherapy improves outcome in young, high-risk patients with follicular lymphoma: pair-matched analysis from the Czech Lymphoma Study Group Database // Leuk. Lymphoma. Leuk Lymphoma, 2017. Vol. 58, № 3. P. 601–613.
55. Metzner B. et al. Long-term outcome in patients with follicular lymphoma following high-dose therapy and autologous stem cell transplantation // Eur. J. Haematol. Eur J Haematol, 2021. Vol. 107, № 5. P. 543–552.
56. Duarte R.F. et al. Indications for haematopoietic stem cell transplantation for haematological diseases, solid tumours and immune disorders: current practice in Europe, 2019 // Bone Marrow Transplant. Nature Publishing Group, 2019. Vol. 54, № 10. P. 1525–1552.